Anti-cancer medicines availability study

Study objectives: to provide European health authorities with data on the availability of licensed anti-neoplastic medicines across Europe. This ESMO study is conducted under the auspices of the ESMO Emerging Countries Committee in collaboration with the World Health Organization, the Kings College London Institute of Cancer Policy, the Union for International Cancer Control, and the European Society of Oncology Pharmacy (liaising with the European Association of Hospital Pharmacy). Read more here.